179 related articles for article (PubMed ID: 31463666)
1. IL-1β, IL-17A, CRP and biologics history might serve as potential markers for clinical response to etanercept in rheumatoid arthritis patients.
Zhang B; Jiang W
Inflammopharmacology; 2019 Dec; 27(6):1123-1130. PubMed ID: 31463666
[TBL] [Abstract][Full Text] [Related]
2. Serum interleukin-6 and survivin levels predict clinical response to etanercept treatment in patients with established rheumatoid arthritis.
Shi R; Chen M; Litifu B
Mod Rheumatol; 2018 Jan; 28(1):126-132. PubMed ID: 28657833
[TBL] [Abstract][Full Text] [Related]
3. Niclosamide as an adjuvant to etanercept in treatment patients with active rheumatoid arthritis: an 8-week randomized controlled pilot study.
Al-Gareeb AIA; Gorial FI; Mahmood AS
Clin Rheumatol; 2018 Oct; 37(10):2633-2641. PubMed ID: 29882203
[TBL] [Abstract][Full Text] [Related]
4. IL-1β, IL-17A and combined phototherapy predicts higher while previous systemic biologic treatment predicts lower treatment response to etanercept in psoriasis patients.
Liu Y; Qin G; Meng Z; Du T; Wang X; Tang Y; Cao J
Inflammopharmacology; 2019 Feb; 27(1):57-66. PubMed ID: 30242748
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-1β, interleukin-6, and interleukin-17A as indicators reflecting clinical response to celecoxib in ankylosing spondylitis patients.
Zhang Y; Ning C; Zhou H; Yan Y; Liu F; Huang Y
Ir J Med Sci; 2021 May; 190(2):631-638. PubMed ID: 32955700
[TBL] [Abstract][Full Text] [Related]
6. JKAP correlates with lower disease risk and inflammation, and its increment during etanercept treatment associates with commendable treatment efficiency in rheumatoid arthritis patients.
Mou XY; Jin D; Zhang Q; Guan JT; Jin Y
Eur Rev Med Pharmacol Sci; 2021 Mar; 25(6):2654-2661. PubMed ID: 33829452
[TBL] [Abstract][Full Text] [Related]
7. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy.
Chen DY; Chen YM; Chen HH; Hsieh CW; Lin CC; Lan JL
Arthritis Res Ther; 2011 Jul; 13(4):R126. PubMed ID: 21801431
[TBL] [Abstract][Full Text] [Related]
8. Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis.
Fabre S; Dupuy AM; Dossat N; Guisset C; Cohen JD; Cristol JP; Daures JP; Jorgensen C
Clin Exp Immunol; 2008 Aug; 153(2):188-95. PubMed ID: 18549443
[TBL] [Abstract][Full Text] [Related]
9. The implication of long non-coding RNA expression profile in rheumatoid arthritis: Correlation with treatment response to tumor necrosis factor inhibitor.
Wang Q; Huang X; Shao Y; Liu Q; Shen J; Xia J; Zhang Z; Wang C
Mod Rheumatol; 2023 Jan; 33(1):111-121. PubMed ID: 35141748
[TBL] [Abstract][Full Text] [Related]
10. Serum high-sensitivity C-reactive protein, tumor necrosis factor-α, interleukin (IL)-1β, IL-17A and IL-23 levels in patients with hidradenitis suppurativa.
Saraç Öztürk G; Ergun T; Peker Eyüboğlu İ; Akkiprik M
Cytokine; 2021 Aug; 144():155585. PubMed ID: 34034145
[TBL] [Abstract][Full Text] [Related]
11. The immunomodulatory effects of TNF-α inhibitors on human Th17 cells via RORγt histone acetylation.
Lin YC; Lin YC; Wu CC; Huang MY; Tsai WC; Hung CH; Kuo PL
Oncotarget; 2017 Jan; 8(5):7559-7571. PubMed ID: 27926504
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
Zivojinovic SM; Pejnovic NN; Sefik-Bukilica MN; Kovacevic LV; Soldatovic II; Damjanov NS
J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
[TBL] [Abstract][Full Text] [Related]
13. Potential applicability of cytokines as biomarkers of disease activity in rheumatoid arthritis: Enzyme-linked immunosorbent spot assay-based evaluation of TNF-α, IL-1β, IL-10 and IL-17A.
Dissanayake K; Jayasinghe C; Wanigasekara P; Sominanda A
PLoS One; 2021; 16(1):e0246111. PubMed ID: 33497394
[TBL] [Abstract][Full Text] [Related]
14. JNK pathway-associated phosphatase associates with rheumatoid arthritis risk, disease activity, and its longitudinal elevation relates to etanercept treatment response.
Sun L; Tu J; Chen X; Dai M; Xia X; Liu C; Zhou Y
J Clin Lab Anal; 2021 Apr; 35(4):e23709. PubMed ID: 33547838
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-1β measurement in stimulated whole blood cultures is useful to predict response to anti-TNF therapies in rheumatoid arthritis.
Kayakabe K; Kuroiwa T; Sakurai N; Ikeuchi H; Kadiombo AT; Sakairi T; Kaneko Y; Maeshima A; Hiromura K; Nojima Y
Rheumatology (Oxford); 2012 Sep; 51(9):1639-43. PubMed ID: 22596214
[TBL] [Abstract][Full Text] [Related]
16. Correlation of microRNA expression profile with clinical response to tumor necrosis factor inhibitor in treating rheumatoid arthritis patients: A prospective cohort study.
Liu Y; Han Y; Qu H; Fang J; Ye M; Yin W
J Clin Lab Anal; 2019 Sep; 33(7):e22953. PubMed ID: 31245894
[TBL] [Abstract][Full Text] [Related]
17. The association of disease activity, pro-inflammatory cytokines, and neurotrophic factors with depression in patients with rheumatoid arthritis.
Cheon YH; Lee SG; Kim M; Kim HO; Sun Suh Y; Park KS; Kim RB; Yang HS; Kim JM; Son CN; Kyoung Park E; Kim SH; Lee SI
Brain Behav Immun; 2018 Oct; 73():274-281. PubMed ID: 29787856
[TBL] [Abstract][Full Text] [Related]
18. Infliximab and etanercept have distinct actions but similar effects on cytokine profiles in rheumatoid arthritis.
Takeshita M; Suzuki K; Kikuchi J; Izumi K; Kurasawa T; Yoshimoto K; Amano K; Takeuchi T
Cytokine; 2015 Oct; 75(2):222-7. PubMed ID: 26095743
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors for effective selection of Interleukin-6 inhibitor and tumor necrosis factor inhibitor in the treatment of rheumatoid arthritis.
Hayashi S; Matsubara T; Fukuda K; Funahashi K; Hashimoto M; Maeda T; Kamenaga T; Takashima Y; Matsumoto T; Niikura T; Kuroda R
Sci Rep; 2020 Oct; 10(1):16645. PubMed ID: 33024253
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo inhibited cytokine profiling may explain inferior treatment response to golimumab after adalimumab failure in rheumatoid arthritis.
Tweehuysen L; Schraa K; Netea MG; van den Hoogen FHJ; Joosten LAB; den Broeder AA
Clin Exp Rheumatol; 2018; 36(1):140-143. PubMed ID: 29148425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
